Evans, Thomas R. Jeffry
Kudo, Masatoshi
Finn, Richard S.
Han, Kwang-Hyub
Cheng, Ann-Lii
Ikeda, Masafumi
Kraljevic, Silvija
Ren, Min
Dutcus, Corina E.
Piscaglia, Fabio
Sung, Max W.
Funding for this research was provided by:
Eisai Inc., Woodcliff Lake, NJ, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Article History
Received: 22 March 2019
Revised: 24 May 2019
Accepted: 5 June 2019
First Online: 28 June 2019
Change Date: 30 July 2019
Change Type: Correction
Change Details: This article was originally published under a standard license to Publish, but has now been made available under a CC BY license. The PDF and HTML versions of the paper have been modified accordingly.An amendment to this paper has been published and can be accessed via a link at the top of the paper
Competing interests
: TRJE: Reports honoraria from Eisai for advisory boards and speaker’s bureau (payable to his institution); support from Eisai for sponsored clinical trials (payable to the institution); honoraria for advisory boards and speaker’s bureau from Bristol-Myers Squibb, Bayer, GlaxoSmithKline, Roche/Genentech (all payable to his institution); honoraria for advisory boards from Celgene, Karus Therapeutics, Baxalta, TC BioPharm, Immunova (all payable to his institution); support for sponsored clinical trials (payable to the institution) from Bristol-Myers Squibb, GlaxoSmithKline, Roche / Genentech, Celgene, TC BioPharm, Merck, Novartis, e-Therapeutics, Vertex, Verastem, Daiichi, AstraZeneca, Basilea, Immunocore, Chugai; support to attend international scientific conferences from Bristol-Myers Squibb, Roche/Genentech, Bayer, Merck, Eisai; he is co-editor of the clinical subjects section of the <i>British Journal of Cancer</i>. MK: Reports grants/research support from Bayer, Daiichi Sankyo, Chugai, Otsuka, Taiho, Sumitomo Dainippon, and Merck Sharp & Dohme Corp; received honoraria from Bayer, Eisai, Merck Sharp & Dohme Corp, BMS, and EA Pharma; and consulting/advisory role for Bayer and Eisai. RSF: Reports grants/research support from Bayer, BMS, Novartis, Pfizer, Eisai, Eli Lilly, and Merck (payable to his institution); provided expert testimony for Novartis; and consulting/advisory role for AstraZeneca, Bayer, BMS, Eisai, Eli Lilly, Novartis, Merck, Pfizer, and Roche/Genentech. K-HH: Reports grants/research support from Eisai and Kowa; and served as a consultant for Eisai, Kowa, and Bayer. A-LC: Reports personal fees for consulting/advisory role for BMS, Ono, Novartis, Bayer, Merck, and Merck Sharp & Dohme Corp. MI: Reports consulting/advisory role for Bayer Yakuhin, Eisai, Novartis Pharma, Shire and MSD; research support from Bayer Yakuhin, Kyowa Hakko Kirin, Yakult, Eli Lilly Japan, Ono Pharmaceutical, Eisai, AstraZeneca, Baxalta Japan Limited, Chugai Pharmaceutical, Bristol-Myers Squibb, Merck Serono, Nano Carrier, ASLAN Pharmaceuticals, Novartis Pharma, and Takara Bio. <b>FP:</b> Reports grant/research support from ESAOTE; received honoraria for advisory/consultant activities from Eisai, AstraZeneca, Bayer, GE, Tiziana Life Sciences; and honoraria for speakers’ bureau from Bayer and Bracco. MWS: Received honoraria for advisory boards from Eisai, Bayer and Exelixis. SK: Former employee of Eisai Ltd. <b>MR</b> and <b>CED</b> are employees of Eisai Inc.
: All relevant institutional review boards approved the protocol for this clinical trial, which was performed in accordance with the Declaration of Helsinki. Ethics committee names are provided in a separate document.
: This study was funded by Eisai Inc., Woodcliff Lake, NJ, and Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. Medical writing assistance was provided by Suhaida A. Selamat, PhD, of Oxford PharmaGenesis Inc., with funding provided by Eisai Inc.
: No identifying patient information is included in this report. All patients signed informed consent forms for the clinical trial.
: The datasets generated during and/or analysed during the current study are on file with Eisai and not publicly available.